Panel votes down heart safety claim for naproxen

Federal health experts say that new research is not strong enough to conclude that naproxen, the pain reliever in Aleve and many other medications, is safer on the heart than rival drugs used by millions of Americans to treat aches and pains.

The Food and Drug Administration advisory panel voted 16-9 against the conclusion that naproxen has a lower risk of and stroke compared with similar anti-inflammatory medications like ibuprofen, sold as Advil and in other generic formulations.

Debate about whether one drug in the class is safer than others has waged for more than a decade without a clear answer.

The FDA convened the meeting this week to consider new analyses that apparently show lower heart risks for . But panelists said the data was not conclusive.


Explore further

FDA: Aleve may be safer on heart than rival drugs

© 2014 The Associated Press. All rights reserved.

Citation: Panel votes down heart safety claim for naproxen (2014, February 11) retrieved 13 July 2020 from https://medicalxpress.com/news/2014-02-panel-votes-heart-safety-naproxen.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments